Skip to main content
SpringerLink
Log in

Non Hodgkin-Lymphome und Interferon-Therapie eingeschlossen Haarzell-Leukämie, ausgeschlossen Multiples Myelom

  • Chapter
Interferone

  • 36 Accesses

Zusammenfassung

Biologisch aktive Steuerfaktoren, zu denen auch die Interferone gezählt werden, entfalten ihre Wirkung auf definierte Zielzellen über Schlüsselprozesse. Ihr Wirkspektrum ist entsprechend eng. Die Non Hodgkin-Lymphome bilden andererseits eine breite, vielgestaltige Gruppe. Ein Ansprechen auf biologische Mediatoren kann daher nur für einzelne Non Hodgkin-Lymphome erwartet werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Jaffe ES (1986) Relationship of Classification to biologic behavior of Non Hodgkin’s lymphomas. Seminars in Oncology 13: 3–9

    PubMed  CAS  Google Scholar 

  2. Gaynor ER, Ultmann JE (1986) Non-Hodgkins’s lymphoma: Management strategies. N Engl J Med 311: 1506–1508

    Google Scholar 

  3. The Non Hodgkins lymphoma classification projekt. Cancer 49:2112–2135 (1982) Fischer R (1986) Zitat. Aktuelle Fragen zur Histopathologic und Klassifikation der Non- Hodgkin Lymphome. Internist 27: 473–484

    Google Scholar 

  4. Binet J, Leporrier M, Dighiero G, Charton D D’Athis, Vaughier G, Merle-Beral H, Natali J, Raphael M, Niset B, Follezon J (1977) A clinical staging system for chronic lymphocytic leukemia. Cancer 40: 855

    Article  PubMed  CAS  Google Scholar 

  5. Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma, correlation of measured myeloma cell mass with presenting clinical features, responses to treatment and survival. Cancer 36: 842–854

    Article  PubMed  CAS  Google Scholar 

  6. Bunn PA Jr, Lamberg SI (1979) Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treatm Rep 63: 725–728

    Google Scholar 

  7. Catovsky D, Quesada Jr, Golomb HM, Golde DN (1987) Consensus resolution: Proposed criteria for evaluation of response to treatment in hairy cell leukemia. Leukemia 1: 405

    Google Scholar 

  8. Burkitt DP (1983) The discovery of Burkitt’s lymphoma. Cancer 51: 1777–1786

    Article  PubMed  CAS  Google Scholar 

  9. Branca AA (1982) Interaction of interferon with cellular receptors. Internalization and degradation of cell bound interferon. J Biol Chem 257: 13291–13296

    PubMed  CAS  Google Scholar 

  10. Faltynek CR, Branca A A, McCandles S, Baglioni C (1983) Characterization of an interferon receptor on human lymphoblastoid cells. Proc Natl Acad Sci, USA 80:3269– 3273

    Google Scholar 

  11. Herbermann RB (1986) Effects of biological response modifiers on effector cells with cytotoxic activity against tumors. Seminars in Oncology 13: 195–204

    Google Scholar 

  12. Samuels BL, Rosner MC, Giometti CS, Golomb HM, Brownstein BH (1987) Actions of interferons in hairy cell leukemia. Leukemia 1: 365–369

    PubMed  CAS  Google Scholar 

  13. Hogeveen YL, Smit JW, Blom NR von Luyn MJA, Halie RM (1988) Interferon-alpha induction of lymphocytes containing parallel tubular structures. Blut 56: 55–61

    Google Scholar 

  14. Levine EG, Arthur DC, Frizzerà G, Peterson BA, Hurd DD, Bloomfield CD (1988) Cytogenetic abnormalities predict clinical outcome in Non-Hodgkin’s Lymphoma. Ann Intern Med 108: 14–20

    PubMed  CAS  Google Scholar 

  15. Bornkamm GW, Polack A, Eick D, Berger R, Lenoir GM (1987) Chromosomentranslokation und Epstein-Barr-Virus beim Burkitt-Lymphom. Onkologie 10: 196–204

    Article  PubMed  CAS  Google Scholar 

  16. Ngan B-Y, Chen-Levy Z, Weiss LM, Warnke RA, Cleary ML (1988) Expression in Non- Hodgkin’s lymphoma of the bcl-2 protein associated with the t (14; 18) chromosomal translocation. N Engl J Med 318: 1638–44

    Article  PubMed  CAS  Google Scholar 

  17. Arnold A, Cossmann J, Bakhski A, Jaffe ES, Waldmann TA, Korsmeyer SJ (1983) Ig- gene rearragement as unic clonal markers in lymphoid neoplasms. N Engl J Med 309: 1593–1598

    Article  PubMed  CAS  Google Scholar 

  18. Waldmann TA, Davis MM, Bongiovanni KF, Korsmeyer SJ (1985) Rearrangements of genes for the antigen receptor on T-cells as markers of lineage and clonality in human lymphoid neoplasms. N Engl J Med 313: 776–783

    Article  PubMed  CAS  Google Scholar 

  19. Harfast B, Huddlestone Jr, Casali P, Merigan TC, Oldstone MBA (1981) Interferon acts directly on human B-lymphocytes to modulate immunoglobulin synthesis. J Immunol 127: 2146–2150

    PubMed  CAS  Google Scholar 

  20. Broder S, Bunn PA, Jaffe ES, Blattner W, Gallo RC, Wong-Staal F, Waldmann TA, De Vita Jr. VT (1984) T-cell lymphoproliferati ve syndrome associated with human T-cell leukemia lymphoma virus. Ann Intern Med 100: 543–545

    PubMed  CAS  Google Scholar 

  21. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Blayney D, Golde DW, Gallo RC (1982) A new subtype of human T-cell leukemia virus ( HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 218: 571

    Google Scholar 

  22. Catovsky S, Greaves MF, Rose M (1982) Adult T-cell lymphoma leukemia in blacks from the West Indies. Lancet 1: 639–643

    Article  PubMed  CAS  Google Scholar 

  23. Rosenblatt JD, Golde DW, Wachsmann W, Jacobs A, Salmon D, Chen ISY (1985) A new HTLV-II-isolate associated with T-cell hairy cell leukemia: Evidence for an etiologic role. Blood 66:245 A

    Google Scholar 

  24. Knowles DM, Chamulak GA, Subar M, Burke JS, Dugan M, Wernz J, Slywotzky C, Pelicci PG, Dalla-Favera R, Raphael B (1988) Lymphoid neoplasia associated with the acquired immunodeficiency syndrome ( AIDS ). Ann Intern Med 108: 744–753

    Google Scholar 

  25. Knight Jr, Anton ED, Fahey D, Friedland BK, Jonak GJ (1985) Interferon regulates c-myc product expression in Daudi cells at the posttranscriptional level. Proc Natl Acad Sci, USA §2: 1151–1154

    Google Scholar 

  26. Clemens M (1986) Interferons and oncogenes. Nature 313: 531–532

    Article  Google Scholar 

  27. Borden EC (1984) Progress towards therapeutic application of interferon. Cancer 54: 2770–2776

    Article  PubMed  CAS  Google Scholar 

  28. Niederle N, Doberauer C, Kloke O, Höffken K, Schmidt CG (1987) Zur Wirksamkeit von IFN-y und IFN-a bei der Haarzellenleukämie. Klin Wochenschr 65: 706–712

    Article  PubMed  CAS  Google Scholar 

  29. von Wussow P, Düllmann J, Grethlein T, Hirschmann WD, Hügl E, Kocxh O, Martin WR, Pees HW, Urbanitz W, Freund M (1987) IFN-ß-Therapie bei der Haarzelleukämie. Klin Wochenschr 65: 688–690

    Article  Google Scholar 

  30. Östlund L, Einhorn S, Rober KH, Juliusson G, Biberfeld P (1986) Chronic B-lymphozyte leukemia cells proliferate and differentiate following exposure to interferon in vitro. Blood 67: 152–159

    PubMed  Google Scholar 

  31. Chilosi M, Semenzato GC, Ambrosetti A, Fiori-Donati L, Perona G, Berton G, Lestani M, Scarpa A, Agostini C, Trentin L, Masciarelli M, Dazzi F, Vinante F, Cagliaris-Cappio F, Pizzolo G (1987) Soluble interleukin–2 receptors in the sera of patients with hairy cell leukemia: Relationship with the effect of recombinant a-Interferon therapy on clinical parameters and natural killer in vitro activity. Blood 70: 1530–1535

    Google Scholar 

  32. Ho AD, Großmann M, Knauf W, Martin H, Zwingers Th, Trümper L, Sonnen R, Pralle H, Hunstein W (1988) Plasma levels of sCD8 and sIL2-R in patients with hairy cell leukemia, relationship with splenectomy and with clinical response to therapy. Submitted

    Google Scholar 

  33. Jones RA, Scott CS, Norfolk DR, Stark AN, Child JA (1987) Cell surface expression of ß-2 microglobulin correlates with stages of differentiation in B-cell tumors. J Clin Pathol 40: 486–489

    Article  PubMed  CAS  Google Scholar 

  34. Jones GJ, Itri LM (1986) Safety and tolerance of recombinant Interferon a 2A in cancer patients. Cancer 57: 1709–1715

    Article  PubMed  CAS  Google Scholar 

  35. Itri LM, Champion M, Dennin RA, Palleroni AV, AV Gutterman JU, Groopman JE, Trown PD (1987) Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon a-2a by intramuscular injection. Cancer 59:668– 674

    Google Scholar 

  36. Horning SJ, Merigan T, Krown S, Gutterman JU, Louie A, Gallagher J, McCravey J, Abramson J, Cabanillas F, Oettgen H, Rosenberg SA (1985) Human interferon alpha in malignant lymphoma and Hodgkin’s disease. Cancer 56: 1305–1310

    Article  PubMed  CAS  Google Scholar 

  37. Meyers JD, Flournoy N, Sanders JE, McGuffin RW, Newton BA, Fisher LD, Lum LG, Appelbaum FR, Doney K, Sullivan KM, Storb R, Buckner CD, Thomas ED (1987) Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. Ann Intern Med 107: 809–816

    PubMed  CAS  Google Scholar 

  38. Fer MF, Bottino GC, Sherwin SA, Hainsworth JD, Abrams PG, Foon KA, Oldham RK (1984) Atypical tumor lysis syndrome in a patient with T cell lymphoma treated with recombinant leukocyte interferon. Amer J Med 77: 953–956

    Article  PubMed  CAS  Google Scholar 

  39. Sohn CC, Blayney DW, Misset JL, Mathe G, Flandrin G, Moran EM, Jensen FC, Winberg CD, and Rappaport H (1986) Leukopenic chronic T cell leukemia mimicking hairy cell leukemia: Association with human retroviruses. Blood, 67: 949–956

    Google Scholar 

  40. Brittinger G, Bartels M, Common M, Dühmke E, Fülle HH, Gunzer U, Gyenes T, Heinz R, König E, Meusers P, Paukstat M, Pralle H, Theml H, Kopeke W, Thieme C, Zwingers T, Musshoff K, Stacher A, Brücher H, Herrmann F, Ludwig WD, Pribilla W, Burger-Schüler A, Lohr GW, Gremmel H, Oertel J, Gerhartz H, Koeppen KM, Boll I, Huhn D, Binder T, Schoengen A, Nowicki L, Pees HW, Scheurlen PG, Leopold H, Wannen- macher M, Schmidt M, Löffler H, Michlmayr G, Thiel E, Zettel R, Rühl U, Wilke HJ, Schwarze EW, Feller AC, Lennert K (1984) Clinical and prognostic relevance of the Kiel classification of non-Hodgkin’s-lymphomas: Results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol 2: 269–306

    PubMed  CAS  Google Scholar 

  41. Sherwin SA, Knost JA, Fein S, Abrams PG, Foon KA, Ochs JJ, Schönberger C, Maluish AE, Oldham R (1984) Phase-1-Versuch mit Mehrfachdosen von Rekombinanten-Leukozyten-A-Interferon bei Krebspatienten. JAMA-D 3 1: 40–46

    Google Scholar 

  42. O’Connell MJ, Colgan JP, Oken MM (1986) Clinical trial of recombinant leukocyt A interferon as initial therapy for favorable histology non-Hodgkin’s lymphomas and chronic lymphatic leukemia. J Clin Oncol 4: 128 - 136

    PubMed  Google Scholar 

  43. Pangalis GA, Griva E (1987) Recombinant alfa-2b-interferon therapy in untreated stages A and B chronic lymphocytic leukemia. Cancer 61: 869–872

    Article  Google Scholar 

  44. Quesada Jr, Hawkins M, Horning S, Alexanian R, Borden E, Merigan T, Adams F, Gutterman JU (1984) Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma and multiple myeloma. Am J Med 77: 427–432

    Article  PubMed  CAS  Google Scholar 

  45. Siegert W (1982) Treatment of Non-Hodgkin’s lymphoma of low-grade malignancy with human fibroblast interferon. Anticancer Res 2: 193–198

    PubMed  CAS  Google Scholar 

  46. Schilsky RL, Dalter S, Golomb HM (1987) Gonodal and sexual function in male patients with hairy cell leukemia: Lack of adverse effects of recombinant a2-interferon treatment. Cancer Treatm Rep 71: 179–181

    CAS  Google Scholar 

  47. Portlock CS, Rosenberg SA (1979) No initial therapy for stage III and IV non-Hodgkin’s lymphomas of favorable histologic types. Ann Intern Med 90: 10–13

    PubMed  CAS  Google Scholar 

  48. Horning SJ, Rosenberg SA (1984) The natural history of initially untreated low-grade Non-Hodgkin’s lymphomas. N Engl J Med 311: 1471–1475

    Article  PubMed  CAS  Google Scholar 

  49. Steis RG, Foon KA, Longo Dan (1987) Current and future uses of recombinant interferon alpha in the treatment of low-grade non-Hodgkin’s lymphoma. Cancer 59: 658–663

    Article  PubMed  CAS  Google Scholar 

  50. Ozer H, Anderson Jr, Peterson BA, Budman DR, Henderson ES, Bloomfield CD, Gottlien A (1987) Combination trial of subsutaneous interferon alfa-2b and oral cyclophosphamide in favorable histology non-Hodgkin’s lymphoma. Investigational New Drugs 5 (Suppl.) 27–33

    Article  Google Scholar 

  51. Ziegler-Heitbrock HWL, Dörken B, Munker R, Riethmüller G, Thierfelder S, Thiel E (1985) In-vitro induction of some features of hairy cell in chronic lymphocytic leukemia and immunocytoma cells. Blut 50: 29–31

    Article  PubMed  CAS  Google Scholar 

  52. Foon K, Bottino GC, Abrams PG, Fer MF, Longo DL, Schoenberger CS, Oldham RK (1985) Phase II trial of recombinant leukocyte a interferon in patients with advanced chronic lymphocytic leukemia. Amer J Med 78: 216–220

    Article  PubMed  CAS  Google Scholar 

  53. Pangalis GA, Griva E (1987) Recombinant alfa-2b-interferon therapy in untreated stages A and B chronic lymphocytic leukemia. Cancer 61: 869 - 872

    Article  Google Scholar 

  54. Louie AC, Gallagher JG, Sikora K, Levy R, Rosenberg SA, Merigan TC (1981) Follow- up observations on the effect of human leukocyte interferon in non-Hodgkin’s lymphoma. Blood 58: 712–718

    PubMed  CAS  Google Scholar 

  55. Stevenson HC, Ochs JJ, Halverson L, Oldham RK, Shervin SA, Foon KA (1984) Recombinant alpha interferon in the treatment of two patients with pulmonary lymphoma: dramatic responses with resolution of pulmonary complications. Am J Med 77:355– 358

    Google Scholar 

  56. Bunn PA, Foon KA, Ihde DC, Longo DL, et al (1984) Recombinant leukocyte a interferon: An active agent in advanced T-cell lymphomas. Ann Intern Med 101: 484–487

    Google Scholar 

  57. Bunn PA Jr, Ihde DC, and Foon KA (1987) Recombinant interferon alpha 2A, an active agent in advanced T-cell lymphomas. Int J Cancer (Suppl) 1: 9–13

    Article  Google Scholar 

  58. Olsen E, Rosen S, Vollmer R, Variakojis D, Zeffren J (1987) Interferon alpha 2A in the treatment of cutaneous T- cell lymphomas. Proc Am Soc Clin Oncol 6: 199

    Google Scholar 

  59. Vonderheid EC, Thompson R, Smiles KA, Lattanand A (1987) Recombinant interferon alpha-2b in plaques-phase mycosis fungoides: intralesional and low-dose intramuscular therapy. Arch Dermatol 123: 757–763

    Article  PubMed  CAS  Google Scholar 

  60. Douglas RM, Moore BW, Miles HB, Lorraine MD, Graham MH, Ryan P, Worswick DA, Albrecht JK (1986) Prophylactic efficacy of intranasal alpha2-Interferon against rhinovirus infections in the family setting. N Engl J Med 314: 65–75

    Article  PubMed  CAS  Google Scholar 

  61. Pralle H, Zwingers Th, Boedewadt S, Bross K, Dörken B, Gamm H, Ho AD, Parwaresch RM, Schmitz N, Papendiek U, Asshoff D, Bremer K, Euler H, Fischer Th, Ganser A, Goldmann A, Hartlapp J Hayungs J, Heinen U, Heyll A, Kraft J, Lohmeyer J, Meier P, Neubauer A, Nowicki L, Pflüger K, Saß R, Schmidt W, Schuster D, Straif K, Westerhausen M (1987) Primäre Behandlung der Haarzelleukämie mit niedrigdosiertem humanem rekombinantem Interferon-alpha 2c (Hr-IFN alpha 2c) im Vergleich zur Therapie nach Splenektomie. Onkologie 10: 5–10

    Article  PubMed  CAS  Google Scholar 

  62. Kraft F, Straif K, Schuster H, Böger M, Eimermacher H, Calavrezos A, Bross K, Pralle H (1986) Lethal infectious complications in patients with hairy cell leukemia under treatment with hum-r-Interferon a2C (arg). Blut 53: 213–214

    Google Scholar 

  63. Flandrin G, Sigaux F, Castaigne S, Calvo F, Sebahoun G, Glot P (1984) Leucemie a tricholeucocytes: etude d’évolution de 211 cas. Nouv Presse Med 13: 2795–2799

    CAS  Google Scholar 

  64. Bouroncle BA, Wiseman BK, Doan CA (1958) Leukemic reticuloendotheliosis. Blood 13: 609–630

    PubMed  CAS  Google Scholar 

  65. Golomb HM (1981) Progress report in chlorambucil therapy in postsplenectomy patients with progressive hairy cell leukemia. Blood 57: 464–467

    PubMed  CAS  Google Scholar 

  66. Bouroncle BA (1986) Persönliche Mitteilung. Leeds Castle 22.–24. Sept. 1986

    Google Scholar 

  67. Yam LT, Li CY, Lam KW (1971) Tartrate resistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendotheliosis. New Engl J Med 284: 357–360

    Article  PubMed  CAS  Google Scholar 

  68. Nanba K, Soban E, Bowling MC, Bernard CW (1977) Splenic pseudosinuses and hepatic angiomatous lesions in hairy cell leukemia. Am J Clin Pathol 67: 451

    Google Scholar 

  69. Kjeldsberg CR (1978) A unique vascular lesion in hairy cell leukemia. Am J Clin Pathol 69: 99 (letter)

    Google Scholar 

  70. Lowe J, Rusell NH (1987) Cerebral vasculitis associated with hairy cell leukemia. Cancer 60: 3025–3028

    Article  PubMed  CAS  Google Scholar 

  71. Zafrani ES, Degos F, Guigui B, Durand-Schneider AM, Martin N, Flandrin G, Benhamon JP, Feldmann G (1987) The hepatic sinusoid in hairy cell leukemia, an ultrastructural study of 12 cases. Hum Pathol 18: 801–807

    Article  PubMed  CAS  Google Scholar 

  72. Seshadri RS, Brown EJ, Zipurski A (1976) Leukemic reticuloendotheliosis: A failure of monocyte production. N Engl J Med 295: 181

    Google Scholar 

  73. Aderka D, Levo Y, Ramot B, Michalevicz R, Meytes D, Shaklai M, Hahn T, Hotmann H, Revel M, Wallach D (1987) Reduced production of tumor necrosis factor by mononuclear cells in hairy cell leukemia patients and improvement following interferon therapy. Cancer 60: 2208–2212

    Article  PubMed  CAS  Google Scholar 

  74. Porzsolt F, Janik R, Heil G, Brudler O, Raghavacher A, Scholz S, Papendiek U, Heimpel H (1986) Deficient IFN alpha production in hairy cell leukemia. Blut, 52: 185–190

    Article  PubMed  CAS  Google Scholar 

  75. Cordingley FT, Hoffbrand AV, Heslop HE, Turner M, Bianci A, Reittie JE, Vyakarnam A, Meager A, Brenner MK (1988) Tumor necrosis factor as autocrine growth factor in chronic malignant B-cell diseases. Lancet I, 969: 971

    Google Scholar 

  76. Ford RJ, Kwok D, Quesada J, Sahasrabuddhe CG (1986) Production of B-cell growth factor(s) by neoplastic B-cells from hairy cell leukemia patients. Blood 67: 573–577

    PubMed  CAS  Google Scholar 

  77. Foa R, Lauria F, Lusso P, Raspadori D, Fierro MT, Tazzari PL, Laudana L, Matera L (1986) Phenotypic and functional characterization of the circulating NK compartment in hairy cell leukemia. Clin Exp Immunol 64: 392–398

    PubMed  CAS  Google Scholar 

  78. Fallini B, Pulford K, Erber WN, Posnett DN, Pallesen G, Schwarting R, Annino L, Cafolla A, Canino S, Mori A, Minelli O, Ciani C, Voxes EE, Golomb HM, Delsol G, Steni H, Martelli MF, Grignani F, Mason DY (1986) Use of a panel of monoclonal antibodies for the diagnosis of hairy cell leukemia. Histopath 10: 671–687

    Article  Google Scholar 

  79. Matsuo Y, Sagawa K, Morita M, Minoweda J, Yokoyama MM (1986) Establishment of a hairy cell leukemia cell line carrying Tac antigen and phagocytic activity with B-cell characteristics. J Natl Cane Inst 76: 207–216

    CAS  Google Scholar 

  80. Hsu SM, Yang, Jaffe ES (1983) Hairy cell leukemia a B-cell neoplasm with a unique antigenic phenotype. Am J Clin Path 80: 421–428

    PubMed  CAS  Google Scholar 

  81. Anderson KC, Boyd AW, Fisher DC, Leslie D, Schlossman SF, Nadler LM (1985) Hairy cell leukemia: A tumor of pre-plasma cells. Blood, 65: 620–629

    Google Scholar 

  82. Saxon A, Stevens RH, Golde DW (1978) Thymphocytic variant of hairy cell leukemia. Ann Intern Med 88: 323–326

    PubMed  CAS  Google Scholar 

  83. Giardina SL, Young HA, Faltynek CR, Jaffe ES, Clark JW, Steis RG, Urba WJ, Matthieson BJ, Gralnick H, Lawrence J, Overton WR, Longo DL (1988) Rearrangement of both immunoglobulin and T-cell receptor genes in a prolymphocyte variant of hairy cell leukemia patient resistant to interferon-alpha. Blood 72: 1708–1716

    PubMed  CAS  Google Scholar 

  84. Kristensen J Sch, Ellegard J, Hokland P (1987) A two flow cytometry assay for detection of hairy cells using monoclonal antibodies. Blood 70: 1063–1068

    Google Scholar 

  85. De Panfilis G, Manara GC, Ferrari C, Torresani C, Sansoni P (1988) Hairy cell leukemia cells express CD la-Antigen. Cancer 61: 52–57

    Article  PubMed  Google Scholar 

  86. Jansen J, Hermans J (1982) Clinical staging system for Hairy-cell Leukemia. Blood 60: 571–577

    PubMed  CAS  Google Scholar 

  87. Yam LT, Chaudry AA, Janchila AJ (1977) Impaired marrow granulocyte reserve and leukocyte mobilization in leukemic reticuloendotheliosis. Ann Intern Med 87: 444–446

    PubMed  CAS  Google Scholar 

  88. Salata RA, King RE, Gose F, Pearson RD (1986) Listeria monocytogenes cerebritis, bacteremia, and cutaneous lesions complicating hairy cell leukemia. Am J Med 81: 1068–72

    Article  PubMed  CAS  Google Scholar 

  89. Myers TJ, Granville NB, Witter BA (1979) Hairy cell leukemia and sarcoid. Cancer 43: 1777–1781

    Article  PubMed  CAS  Google Scholar 

  90. Stewart DJ, Bodey GP (1981) Infections in hairy cell leukemia. Cancer 47: 801–805

    Article  PubMed  CAS  Google Scholar 

  91. Golomb HM, Hadad LJ (1984) Infections complications in 127 patients with hairy cell leukemia. Am J Hematol 16: 393–401

    Article  PubMed  CAS  Google Scholar 

  92. Knecht H, Rhyner K, Streuli RA (1986) Toxoplasmosis in hairy cell leukemia. Br J Haematol 62: 65–73

    Article  PubMed  CAS  Google Scholar 

  93. Nielsen H, Bangsborg J, Rechnitzer C, Jacobsen N, Busk HE (1986) Defective monocyte function in legionnaires’ disease complicating hairy cell leukemia. Acta med Scand 220: 381–383

    Article  PubMed  CAS  Google Scholar 

  94. Kaplan RP, Newmann G, Saperia D (1987) Pyoderma gangraenosum and hairy cell leukemia. J Dermatol Surg Oncol 13: 1029–1931

    PubMed  CAS  Google Scholar 

  95. Pralle H, Loffler H, Graubner M, Roux A und Fischer J (1979) Therapieergebnisse bei Hairy-cell-Leukamie. Onkologie 2: 87–90

    Google Scholar 

  96. O’Dwyer PJ, Spiers ASD, Marsoni S (1986) Association of severe and fatal infections and treatment with Pentostatin. Cancer Treatm Reports 70: 1–17

    Google Scholar 

  97. Ohyashitei K-JH, Takeuchi J, Han T, Henderson ES, Sandberg AA (1987) Cytogenetic studies in hairy cell leukemia. Cancer Genet Cytogenet 24: 109–117

    Article  Google Scholar 

  98. Rosenblatt JD, Giorgi JV, Golde DW, Ezra JB, Wu A, Winberg CD, Glaspy J, Wachsmann W, Chen IS (1988) Integrated human T-cell leukemia virus II genome in CD8 4- cells from a patient with atypical hairy cell leukemia: evidence for distinct T and B cell lymphoproliferative disorders. Blood 71: 363–369

    PubMed  CAS  Google Scholar 

  99. Katayama J, Maruyma K, Fukushima T, Nishibe Y, Kayano H (1987) Cross reacting antibodies to human T-cell leukemia virus-I and -II in japanese patients with hairy cell leukemia. Leukemia 1: 401–404

    PubMed  CAS  Google Scholar 

  100. Lehn P, Sigaux F, Grausz D, Loisean P, Castaigne S, Degos L, Flandrin G, Danty F C-myc and c-fos expression during interferon therapy for hairy cell leukemia. Blood 68: 967–970

    Google Scholar 

  101. Pinto A, Coletta G, Del Vecchio L, Resati R, Attadia V, Cimino R, Colombatti A (1987) c-fos oncogene expression in human haematopoietic malignancies is restricted to acute leukemias with monocytis phenotype and to subsets of B-cell leukemias. Blood 70: 1450–1457

    Google Scholar 

  102. Paganelli KA, Evans SS, Han T, Ozer H (1986) B cell growth factor-induced proliferation of hairy cell lymphocytes and inhibition by type I interferon in vitro. Blood 67: 937–942

    PubMed  CAS  Google Scholar 

  103. Korsmeyer SJ, Greene WC, Waldmann TA (1984) Cellular origin if hairy cell-leukemia malignant B-cells that express receptors for T-cell growth factor. Semin Oncol 11: 394–400

    PubMed  CAS  Google Scholar 

  104. Dadmarz R, Evans T, Secher D, Marshall N, Chowley JC (1987) Hairy cells possess more interferon receptors than other lymphoid cell types. Leukemia 1: 357–361

    PubMed  CAS  Google Scholar 

  105. Westbrook Ca, Groopman JE, Golde DW (1984) Hairy cell leukemia: Disease pattern and prognosis Cancer 54: 500–506

    Article  PubMed  CAS  Google Scholar 

  106. Van Norman AS, Nagorney DM, Martin JK, Phyliky RL, Ilstrup DM (1985) Splenectomy for hairy cell leukemia a clinical review of 63 patients. Cancer 57: 644–648

    Article  Google Scholar 

  107. Mage MJ, McKenzie S, Filippa DA, Arlin ZA, Gee TS, Clarkson BD (1985) Hairy cell leukemia: Durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients. Cancer 56: 2557–2562

    Article  Google Scholar 

  108. Ratain MJ, Vardiman JW, Barker CM, Golomb M (1988) Prognostic variables in hairy cell leukemia after splenectomy as initial therapy. Cancer 62: 2420–2424

    Article  PubMed  CAS  Google Scholar 

  109. Klein HG, Balow JE, Dau PC, Hamburger MI, Leitmann SF, Pineda AA (1986) Clinical applications of therapeutic apheresis. J Clin Apheresis 3: 1–92

    Article  Google Scholar 

  110. Miehlke CH, Dobbs CE, Winkler CF, Young LT (1982) Therapeutic leukapheresis in hairy cell leukemia. Arch Intern Med 142: 700–702

    Article  Google Scholar 

  111. Orringer EP, Varia MA (1980) A role for radiation in the treatment of hairy cell leukemia complicated by massive lymphadenopathy. Cancer 45: 2047–2050

    Article  PubMed  CAS  Google Scholar 

  112. Levine MA, Toback AC (1987) Enhancement of granulopoiesis by lithium carbonate in a patient with hairy cell leukemia. Am J Med 82: 146–148

    Article  PubMed  CAS  Google Scholar 

  113. Lenner P, Osterman B, Roos G (1985) Response to oxymetholone in hairy cell leukemia. Scand J Haematol 35: 374–375 (letter)

    Google Scholar 

  114. Joosten P, Hagenbeek A, Löwenberg B, Sizzoo W (1985) High-dose methotrexate with leucovorin rescue: Effectiveness in relapsed hairy cell leukemia. Blood 66: 241–242

    Google Scholar 

  115. Spiers AS, Moore D, Cassileth PA, Harrington DP, Cummings FJ, Neuman RS, Bennet JM, O’Connell MJ (1987) Remissions in hairy cell leukemia with pentostatin (2’DCF). N Engl J Med 316: 825–830

    Article  PubMed  CAS  Google Scholar 

  116. Urba WJ, Smith JW, Longo DL, Baseler MW, Kopp WC, Clark JW, Steis RG (1988) Desoxycoformycin (DCF) causes profound T-cell dysfunction in patients with hairy cell leukemia. Proc Am Ass Clin-Oncol 7: 166 (C642)

    Google Scholar 

  117. Ho AD, Kuse R, Prümmer O, Porzolt F, Hunstein W (1987) 2′-Desoxycoformycin (Pentostatin) in hairy cell leukemia: Response in patients refractory to interferon alpha. Klin Wochenschr 65: 975–979

    Google Scholar 

  118. O’Dwyer PJ, Wagner B, Leyland-Jones B, Wittes R, Cheson BD, Hoth DF (1988) 2- Desoxycoformycin (Pentostatin) for lymphoid malignancies. Rational development of an active drug. Ann Intern med 108: 733–743

    Google Scholar 

  119. Bouroncle BA (1987) Unusual presentations and complications of hairy cell leukemia. Leukemia 1: 288–293

    PubMed  CAS  Google Scholar 

  120. Keefer MJ, Weber MJ, Bottomley SS, Solanki DL, Hosty TA (1987) Peripheral blood remission of hairy cell leukemia after transfusion hepatitis. Am J Hematol 25: 277–284

    Article  PubMed  CAS  Google Scholar 

  121. Hersh EM, Murphy S, Zander A, Dicke K, Stewart DJ, Toki H, Latreille J (1980) Host defense deficiency in hairy cell leukemia and its correction by leukocyte transfusion. Blood 56: 526–533

    PubMed  CAS  Google Scholar 

  122. Cheever MA, Fefer A, Greenberg PD (1982) Treatment of hairy cell leukemia with chemoradiotherapy and identical twin bone marrow transplantation. N Engl J Med 307: 479–481

    Article  PubMed  CAS  Google Scholar 

  123. Glaspy JA, Baldwin GC, Robertson PA, Souza L, Vincent M, Ambersley J, Golde DW (1988) Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Inter Med 109: 789–795

    CAS  Google Scholar 

  124. Fagnet GB, Satya Prakash KL, Agee JF (1988) Cytochemical cytogenetic immunophenotypic and tumorgenic characterization of two hairy cell lines. Blood 71: 422–429

    Google Scholar 

  125. Hooper WC, Barth RF, Houchens DP, Nines R (1987) Effect of dimethylsulfoxide and hexamethylene bisacetamide on the IOK-1 hairy cell leukemia derived cell line propagated in the nude mouse. Exp Cell Biol 55: 93–103

    PubMed  CAS  Google Scholar 

  126. Hiraoka A, Golomb HM (1986) Responses of hairy cell leukemia cells to a recombinant alpha 2-interferon in vitro an in vivo correlation between formation of tubuloreticular structures and clinical parameters. J Biol Response Mod 5: 270–281

    PubMed  CAS  Google Scholar 

  127. Genot E, Mathiot C, Kolb JP (1987) Modulation of the response to B-cell growth factor ( BCGF) of hairy cells from a patient unter interferon-alpha therapy. Blut 55: 65–67

    Google Scholar 

  128. Mongini P, Blessinger C, Seremetis S, Rudich S, Winchester R, Brunda M (1988) Diversity in inhibitory effects of IFN-x and IFN-aA on the induced DNA-synthesis of a hairy cell leukemia clone reflects the nature of the activating ligand. Blood 72: 1553–1559

    PubMed  CAS  Google Scholar 

  129. Quesada Jr, Lepe-Zuniga JL, Gutterman JU (1987) Mid-term observations of the efficacy of a-interferon in hairy cell leukemia and status of the interferon system of patients in remission. Leukemia 1: 317–319

    PubMed  CAS  Google Scholar 

  130. Quesada Jr, Hersh EM, Gutterman JU (1984) Treatment of hairy cell leukemia with alpha Interferon. Proc Amer Soc Clin Oncol 3:207, C-806

    Google Scholar 

  131. Quesada Jr, Hersh EM, Reuben J, Gutterman JU (1985) Treatment of hairy cell leukemia (HCL) with recombinant-DNA derived interferon alpha (rIFNaA). Proc Amer Soc Clin Oncol 4:222, C-864

    Google Scholar 

  132. Glaspy JA, Jacobs AD, Golde DW (1987) The ucla experience with type I interferons in hairy cell leukemia. Leukemia 4: 323–326

    Google Scholar 

  133. Castaigne S, Sigaux F, Cantell K, Falcoff E, Boiron M, Flandrin G, Degos L (1986) Interferon alpha in the treatment of hairy cell leukemia. Cancer 57: 1681–1684

    Article  PubMed  CAS  Google Scholar 

  134. Worman CP, Netherseil AB, Bottomley JM, Apostolow K, Barker W, Cawley JC (1987) Natural interferon a therapy in hairy cell leukemia ( Namalva-type IFN - Wellferon ). Klin Wochenschr 65: 685–687

    Google Scholar 

  135. Steis RG, Smith JW, Urba WJ, Clark JW, Loretta MI, Evans LM, Schoenberger C, Longo DL (1988) Resistance to recombinant interferon a-2a in hairy-cell-leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318: 1409–1413

    Article  PubMed  CAS  Google Scholar 

  136. Quesada Jr, Hersh EM, Gutterman JU (1984) Biologic therapy of hairy cell leukemia. Seminars in Oncology 11: 507

    PubMed  CAS  Google Scholar 

  137. Krown SE (1986) Interferons and interferon inducers in cancer treatment. Seminars in Oncology 13: 207–217

    PubMed  CAS  Google Scholar 

  138. Smalley RV, Tuttle R, Anderson S, Wisnant J, Huang A, Connors J (1988) Is low-dose a-interferon (Wellferon®) effective in hairy cell leukemia? Blood 72: (Suppl. 1) 208a

    Google Scholar 

  139. Golomb HM, Ratain MJ, Fefer A, Thompson J, Portlock CS, Ozer H, Chiaviello J, Israel RJ (1988) Low dose a-2b interferon (0.2 MU/m2 thrice wee kly) for the induction of remission in hairy cell leukemia. Blood 72, (Suppl. 1) 201 a)

    Google Scholar 

  140. Porzsolt F, Thomä J, Unsold M, Wolf W, Obert HJ, Kubanek B, Heimpel H (1985) Platelet adjusted IFN-dosage in the treatment of advanced hairy cell leukemia. Blut 51: 73–82

    Article  PubMed  CAS  Google Scholar 

  141. Lang A, Niederwieser D, Huber C (1984) Treatment with human recombinant interferon a-2 induces increase of in vivo neopterin excretion in Biochemical Aspects of Pteridines, Vol 3, Eds Pfleiderer W, Wächter A, Curtius C, Walter de Gruyter & Co., Berlin-New-York 1984 S. 251–254

    Google Scholar 

  142. Gastl G, Denz H, Abbrederis C, Huber H, Troppmair J, Wiegele J, Niederwieser D, Flener R, Huber C (1985) Treatment with low dose human recombinant interferon alpha-2ARG induces complete remission in hairy cell leukemia. Onkologie 8: 143–144

    Article  PubMed  CAS  Google Scholar 

  143. Kloke O, May D, Wandl U, Niederle N (1988) Zur Dosierung von Interferon alpha in der Induktions- und Erhaltungstherapie der Haarzellenleukämie. Onkologie 11: 41–45

    Article  PubMed  Google Scholar 

  144. Clark R, Dimitrov N, Axelson J, Penner J, Oviatt D (1985) Low dose intermittent IFN in the treatment of hairy cell leukemia. Proc Amer Soc Clin Oncol 4: 161–626

    Google Scholar 

  145. Pralle H, Zwingers Th, Boedewadt S, Bross K, Dörken B, Gamm H, Ho AD, Parwaresch RM, Schmitz N, Papendiek U, Asshoff D, Bremer K, Euler H, Fischer Th, Ganser A, Goldmann A, Hartlapp J, Hayungs J, Heinen U, Heyll, Kraft J, Lohmeyer J, Meier P, Neubauer A, Nowicki L, Pflüger K, Saß R, Schmidt W, Schuster D, Straif K, and Westerhausen M (1987) A prospektive multicenter trial with human recombinant alpha 2c-Interferon in hairy cell leukemia before and after splenectomy. Leukemia 1: 337–340

    PubMed  CAS  Google Scholar 

  146. Golomb HM, Ratain MJ, Fefer A, Thompson J, Golde DW, Ozer H, Portlock C, Silver R, Rappeport J, Bonnern E (1987) Randomized study of the duration of treatment with interferon alpha-2b in patients with hairy cell leukemia. J Natl Cancer Inst 80:369– 373

    Google Scholar 

  147. Dinarello CA, Bernheim HA, Dieff GW, Le HV, Nagabhushan TL, Hamilton NC, Coceani F (1984) Mechanism of fever induced by recombinant human interferon. J Clin Invest 74: 906–913

    Article  PubMed  CAS  Google Scholar 

  148. Aulitzky W, Gastl G, Troppmair J, Tilg H, Abbrederis K, Neri C, Flener R, Huber C (1985) Ergebnisse einer Phase Ii-Studie zur Behandlung von Haarzell-Leukämien mit unterschiedlichen Dosen von alpha-2-rekombinantem Interferon. Acta Med Austriaca 12: 115–121

    PubMed  CAS  Google Scholar 

  149. Abrams PG, McClamrock E, Foon KA (1985) Evening administration of alpha interferon. N Engl J Med 312: 443–444

    Article  PubMed  CAS  Google Scholar 

  150. Bevan PC, Wreghitt TG, King M (1985) Legionnaires’ disease and hairy cell leukemia. J Infect 11: 173–175

    PubMed  CAS  Google Scholar 

  151. Chowdhury VJ, Oscier DG, Mufti GJ, Hamblin TJ (1985) Hairy cell leukemia and legionnaires’ disease. Brit J Dis Chest 79: 393–395

    Article  PubMed  CAS  Google Scholar 

  152. Golomb HM, Fefer A, Golde DW, Ozer H, Portlock C, Silber R, Rappeport J, Ratain MJ, Thompson J, Bonnern EM (1987) Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia. Semin Onkol 14: 13–17

    CAS  Google Scholar 

  153. Dierkx RA, Michotte A, Schmedding E, Ebinger G, Degceter T, van Camp B (1985) Unilateral seizures in a patient with hairy cell leukemia treated with interferon. Clin Neurol Neurosurg 87: 209–212

    Article  Google Scholar 

  154. Bernusen PL, Wong Chung RE, Vingerhoets HM, Jansen JT (1988) Bilateral neuralgic amyotrophy induced by interferon treatment. Arch Neurol 45: 449–451

    Article  Google Scholar 

  155. Westbrook CA, Golde DW (1985) Autoimmune disease in hairy cell leukemia: Clinical syndromes and treatment. Brit J Haematol 61: 349–356

    Google Scholar 

  156. Duncombe AS, Dalton RG, Savidge GF (1987) Lupus-type coagulation inhibitor in hairy cell leukemia and resolution with splenectomy. Brit J Haematol 65: 120–121 (letter)

    Article  CAS  Google Scholar 

  157. O’Donnell Jr, Keen CM (1987) Haemolysis of unusual antibody specificity in hairy cell leukemia. Br J Haematol 65: 499–505 (letter)

    Article  PubMed  Google Scholar 

  158. Quesada Jr, Hersh EM, Gutterman JU (1984) Biologic therapy of hairy cell leukemia. Seminars in Oncology 11: 507

    PubMed  CAS  Google Scholar 

  159. Hermann J, Gabriel F (1987) Membranoproliferative glomerulonephritis in a patient with hairy-cell leukemia treated with alpha 2 Interferon. N Engl J Med 316: 112–113 (letter)

    Article  Google Scholar 

  160. Von Wussow P, Freund M, Block DH, Poliwoda H, Deicher H (1987) Clinical significance of anti-IFN-a antibody titres during interferon therapy. Lancet 2: 635–636 (letter)

    Google Scholar 

  161. Groopman JE (1985) Therapeutic options in hairy cell leukemia. Semin Oncol 4 (Suppl. 5): 30–34

    Google Scholar 

  162. Lembersky BC, Ratain MJ, Golomb HM (1988) Skeletal complications in hairy cell leukemia: Diagnosis and therapy. J Clin Oncol 6: 1280–1284

    Google Scholar 

  163. Catovsky D, Quesada Jr, Golomb HM (1987) Guidelines for the treatment of hairy cell leukemia. Leukemia 1: 405–408

    PubMed  CAS  Google Scholar 

  164. Ratain MJ, Vardiman JW, Barker CM, Golomb HM (1988) Prognostic variables in hairy cell leukemia after splenectomy as initial therapy. Cancer 62: 2420–2424

    Article  PubMed  CAS  Google Scholar 

  165. Rai K, Mick R, Ozer H, Silver R, Papish S, Bloomfield C (1987) a interferon therapy in untreated active hairy cell leukemia: a Cancer and Acute Leukemia Group (CALGB) Study. Proc Am Soc Clin Oncol 6:159 (Abstract 624)

    Google Scholar 

  166. Marziarz RT, Tepler I, Antin JH, Keroack MA, Churchill WH, Holmes W, Rappeport J (1988) Reversal of infection with mycobacterium avium intracellulare by treatment with a interferon in a patient with hairy cell leukemia. Ann Intern Med 109: 292–294

    Google Scholar 

  167. Cheson BD, Martin A (1987) Clinical trials in hairy cell leukemia. Current status and future directions. Ann Intern Med 106: 871–878

    Google Scholar 

  168. Nerenstone S, Martin A, Urba W, Lawrence J, Clark J, Smith J, Crum E, Miller R, Schoenberger C, Hawkins M, Longo D, Steis R (1988) Treatment of hairy cell leukemia (HCL) with alternating cycles of 2’deoxycoformycin (DCF) and recombinant alpha-2a interferon (IFN). Proc Amer Soc Clin Oncol 7:176–679

    Google Scholar 

Download references

Authors
  1. H. W. Pralle
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Med. Klinik III - Onkologie und Hämatologie, Städtisches Krankenhaus, Dhünnberg 60, D-5090, Leverkusen, Deutschland

    Norbert Niederle

  2. Abteilung Immunologie und Transfusionsmedizin, Medizinische Hochschule Hannover, Konstanty-Gutschow-Str. 8, D-3000, Hannover 61, Deutschland

    Peter von Wussow

  3. Zentrum für Innere Medizin und Dermatologie, Medizinische Hochschule Hannover, Konstanty-Gutschow-Str. 8, D-3000, Hannover 61, Deutschland

    Peter von Wussow

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Pralle, H.W. (1990). Non Hodgkin-Lymphome und Interferon-Therapie eingeschlossen Haarzell-Leukämie, ausgeschlossen Multiples Myelom. In: Niederle, N., von Wussow, P. (eds) Interferone. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-93383-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93383-7_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-93384-4

  • Online ISBN: 978-3-642-93383-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation